“Over the past 13 years, I had the greatest opportunity to exploit my passion for science at IPST by contributing to the design, and validation of unique assays which are now routinely run and serve to quantify the efficacy in preclinical drug candidates. My greatest contribution was to see the increase in demand for efficacy services such as the rodent model of pulmonary arterial hypertension (PAH), as well as our intravascular thrombosis and hemostasis models.” Charles completed his doctorate in Pharmacology at the Université de Montreal followed by 4 years of post doctorate studies at the University of Pittsburgh in the Department of Molecular Genetics and Biochemistry. His field of expertise includes cardiovascular pharmacology and molecular biology.
Connect with Charles-E. Laurent
LPS-induced Acute Lung Injury
Purpose
The purpose of this study is to evaluate development of acute lung injury in mice in terms of endpoint measurements of TNFα, IL-6, myeloperoxidase activity, as well as total cells and proportion of neutrophils in brochoalveolar fluid (BALF).
Method
Male C57BL/6 mice weighing between 20 and 25 g will be given food and water ad libitum. Animals will be housed in groups of 3. The animals will be randomly assigned to each experimental group.
Group 1. Control mice (5 mice)
Group 2. LPS + vehicle (8 mice)
Group 3. LPS + test article (8 mice)
Study outcome
- Arterial oxygen saturation and heart rate
- Lung oedema
- Lung histology (H&E staining)
- Total cell count and numbers of neutrophils determined from the BALF pellets for each mouse and expressed as number of cells per mL BAL fluid
- TNFα and IL-6 protein quantification and myeloperoxidase (MPO) activity measured in the BALF supernatant of each mouse and expressed as the concentration per mL BAL fluid, or units MPO.
Compliance
Non-GLP compliant. The study is for a discovery-phase preclinical project.
Species
Mice
Charles-E. Laurent
Ph.D., Director of In-Vivo Pharmacology
